Posted by admin on May 27th, 2022
DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a report issued on Thursday.
Other equities analysts have also issued reports about the stock. Credit Suisse Group dropped their price target on shares of DENTSPLY SIRONA from $68.00 to $67.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 1st. Bank of America lowered shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and dropped their price target for the company from $66.00 to $49.00 in a research note on Tuesday, April 19th. Robert W. Baird lowered shares of DENTSPLY SIRONA from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $67.00 to $48.00 in a research note on Tuesday, April 19th. HC Wainwright decreased their price objective on DENTSPLY SIRONA from $58.00 to $48.00 and set a “hold” rating for the company in a report on Friday, April 22nd. Finally, The Goldman Sachs Group decreased their price objective on DENTSPLY SIRONA from $59.00 to $47.00 and set a “neutral” rating for the company in a report on Thursday, April 21st. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $52.89.
Shares of XRAY stock traded up $0.37 during trading hours on Thursday, reaching $38.95. 1,635,097 shares of the stock were exchanged, compared to its average volume of 2,282,363. The business’s fifty day moving average is $43.72 and its two-hundred day moving average is $50.03. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.45 and a quick ratio of 1.03. DENTSPLY SIRONA has a 12-month low of $35.00 and a 12-month high of $67.69. The firm has a market capitalization of $8.39 billion, a P/E ratio of 23.05 and a beta of 0.94.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) last released its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. DENTSPLY SIRONA had a net margin of 8.81% and a return on equity of 11.63%. The firm had revenue of $9.67 billion for the quarter, compared to analyst estimates of $982.05 million. During the same period in the prior year, the firm earned $0.72 earnings per share. The business’s quarterly revenue was up 841.1% compared to the same quarter last year. As a group, equities research analysts predict that DENTSPLY SIRONA will post 2.41 earnings per share for the current fiscal year.
In related news, Director Eric Brandt sold 6,900 shares of DENTSPLY SIRONA stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total transaction of $273,999.00. Following the completion of the sale, the director now owns 35,155 shares in the company, valued at approximately $1,396,005.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.76% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in DENTSPLY SIRONA by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 24,333,490 shares of the medical instruments supplier’s stock worth $1,197,694,000 after buying an additional 477,563 shares during the last quarter. BlackRock Inc. boosted its stake in DENTSPLY SIRONA by 36.1% in the 1st quarter. BlackRock Inc. now owns 24,083,158 shares of the medical instruments supplier’s stock worth $1,185,372,000 after buying an additional 6,382,605 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in DENTSPLY SIRONA by 17.8% in the 1st quarter. First Eagle Investment Management LLC now owns 8,460,416 shares of the medical instruments supplier’s stock worth $416,422,000 after buying an additional 1,276,404 shares during the last quarter. Wellington Management Group LLP boosted its stake in DENTSPLY SIRONA by 83.1% in the 1st quarter. Wellington Management Group LLP now owns 5,502,424 shares of the medical instruments supplier’s stock worth $270,829,000 after buying an additional 2,497,773 shares during the last quarter. Finally, Champlain Investment Partners LLC boosted its stake in DENTSPLY SIRONA by 0.6% in the 1st quarter. Champlain Investment Partners LLC now owns 5,469,375 shares of the medical instruments supplier’s stock worth $269,203,000 after buying an additional 33,130 shares during the last quarter. Hedge funds and other institutional investors own 94.79% of the company’s stock.
DENTSPLY SIRONA Company Profile (Get Rating)
DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
Marvell Technology (NASDAQ:MRVL) Announces Earnings Results, Beats Expectations By $0.01 EPS
$0.29 Earnings Per Share Expected for Viomi Technology Co., Ltd (NASDAQ:VIOT) This Quarter